Showing results (71-80 of 168) with videos related to
Sort By:
Pageof 17
Pharmacotherapy|August 28, 2010
The essential research curriculum for doctor of pharmacy degree programs, Mary W Lee, Patrick G Clay, et al.Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.Pharmacotherapy|February 10, 2018
Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart FailureRichard H Tran, Ahmed Aldemerdash, Patricia Chang, et al.European Journal of Heart Failure|June 27, 2023
Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysisDaniel Modin, Mats Christian Højbjerg Lassen, Brian Claggett, et al.Diabetes Care|July 11, 2020
Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort StudyDaniel Modin, Brian Claggett, Lars Køber, et al.Journal of Medical Internet Research|October 7, 2022
Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled TrialNell J Marshall, Jennifer L Lee, Jessica Schroeder, et al.Nature Medicine|May 10, 2026
The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trialJohann Bauersachs, Scott D Solomon, Stefan D Anker, et al.Circulation. Heart Failure|November 14, 2019
Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/ValsartanApril F Mohanty, Emily B Levitan, John A Dodson, et al.European Journal of Heart Failure|January 25, 2024
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trialJohann Bauersachs, Scott D Solomon, Stefan D Anker, et al.Journal of Cardiac Failure|May 14, 2013
Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research NetworkSherry K Milfred-Laforest, Sheryl L Chow, Robert J Didomenico, et al.Pageof 17